^
    Back
    Association details:
    Biomarker:Chr t(11;14)
    Cancer:Multiple Myeloma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Darzalex (daratumumab) (CD38 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    338 Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study

    Published date:
    11/02/2023
    Excerpt:
    VenDd achieved 96% ORR, 93% ≥ very good partial response (VGPR), 67% ≥ CR...VenDd treatment showed higher rates of MRD-negativity and sustained MRD-negativity compared to DVd in patients with t(11;14)-positive RRMM, which was associated with longer PFS with VenDd.
    Secondary therapy:
    dexamethasone
    Trial ID:
    VenDd
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    4548 Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

    Published date:
    11/03/2022
    Excerpt:
    This analysis aimed to select the optimal venetoclax dose in combination with daratumumab and dexamethasone (VenDd) in t(11;14)-positive relapsed/refractory MM patients using data from Study M15-654 (NCI: NCT03314181) which evaluated VenDd versus bortezomib in combination with daratumumab and dexamethasone (DVd)...compared to the control arm, venetoclax resulted in higher response rates (very good partial response or better [≥VGPR] and complete response or better [≥CR]) and longer PFS (PFS data not mature at time of analysis).
    Secondary therapy:
    dexamethasone
    DOI:
    https://doi.org/10.1182/blood-2022-166429
    Trial ID:
    VenDd
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

    Published date:
    08/13/2021
    Excerpt:
    The 18-month progression-free survival rate was 90.5% (95% CI, 67.0 to 97.5) with VenDd and 66.7% (95% CI, 42.5 to 82.5) with VenDVd….VenDd and VenDVd produced a high rate of deep and durable responses in patients with RRMM. These results support continued evaluation of venetoclax with daratumumab regimens to treat RRMM, particularly in those with t(11;14).
    Secondary therapy:
    bortezomib + dexamethasone
    DOI:
    10.1200/JCO.21.00443
    Trial ID:
    VenDd